Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EXOZ | 424B5 | bearish | 6/10 | Exozymes is raising $565,206 net proceeds via a registered direct offering of 71,110 shares and 35,555 warrants, priced | Jun 30, 2026 |
| DYN | CLUSTER | neutral | 5/10 | Three Dyne Therapeutics insiders sold a combined $5.02M in shares over a 6-day window, led by Director Rhodes ($4.9M). C | Jun 30, 2026 |
| SEPN | CLUSTER | neutral | 2/10 | Two insiders at Septerna sold a total of $357K in shares over a week, representing a trivial 0.02% of the $1.6B market c | Jun 30, 2026 |
| XTLB | 20-F | bearish | 7/10 | XTL Biopharmaceuticals filed its FY2025 20-F revealing a net loss of $6.97M, cash of only $76k, and an accumulated defic | Jun 30, 2026 |
| NCEL | 6-K | neutral | 2/10 | NewcelX Ltd. filed a Form 6-K reporting that at its June 30, 2026 Annual General Shareholders' Meeting, all proposals we | Jun 30, 2026 |
| IRON | CLUSTER | neutral | 2/10 | Two C-suite insiders at Disc Medicine (IRON) sold a total of $209K in open-market shares over a 4-day window, all via sa | Jun 30, 2026 |
| IONS | CLUSTER | neutral | 2/10 | Four IONIS executives, including CEO Brett Monia, sold a total of $7.22M in open-market shares over a three-day window. | Jun 30, 2026 |
| CPRX | DEFA14A | neutral | 3/10 | Catalyst Pharmaceuticals filed a DEFA14A supplement to its definitive proxy statement for the July 8, 2026 special meeti | Jun 30, 2026 |
| JUNS | 8-K | neutral | 2/10 | Jupiter Neurosciences appointed Dr. Tomas J. Philipson, a health economist with former senior U.S. government roles (Act | Jun 30, 2026 |
| NVCT | 424B5 | bearish | 6/10 | Nuvectis Pharma is offering 5,000,000 shares at $20.00 per share (30% discount to the last close of $28.53), raising $93 | Jun 30, 2026 |
| FF | 8-K | neutral | 2/10 | FutureFuel Corp. declared its Q3 2026 cash dividend of $0.01 per share, payable on September 18, 2026 to shareholders of | Jun 30, 2026 |
| PRGO | 8-K | neutral | 2/10 | Perrigo appointed Salman Amin and Omer Gajial as independent directors, expanding the board from 8 to 10 members. Both b | Jun 30, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 83,530 shares for €2.1M under its existing buyback program between | Jun 30, 2026 |
| MLYS | 144 | neutral | 3/10 | CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is | Jun 30, 2026 |
| APVO | 8-K | bullish | 5/10 | Aptevo Therapeutics secured a $1.5M non-dilutive grant from the Andy Hill CARE Fund to support IND-enabling studies for | Jun 30, 2026 |
| CRNX | PRESS-RELEASE | neutral | 1/10 | Crinetics Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jun 30, 2026 |
| VCEL | CLUSTER | neutral | 2/10 | Four Vericel Corp executives sold shares totaling ~$1.14M on June 26, 2026, all coinciding with option exercises. The sa | Jun 30, 2026 |
| ALXO | 8-K | neutral | 3/10 | ALX Oncology announced the resignation of co-founder and Chairman Corey Goodman, Ph.D., effective June 29, 2026, for per | Jun 30, 2026 |
| QURE | 144 | neutral | 2/10 | Director Jack Kaye filed a Form 144 to sell 21,167 ordinary shares (~$983K) as part of a pre-existing 10b5-1 plan adopte | Jun 30, 2026 |
| XCUR | 8-K | neutral | 2/10 | Exicure, Inc. reported the resignation of director Ham Jung Kyu (effective June 30, 2026), a board size increase from fi | Jun 30, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a routine Form 6-K on June 30, 2026, with an attached intimation (Exhibit 99.1). The fili | Jun 30, 2026 |
| CELZ | PRESS-RELEASE | bearish | 7/10 | Creative Medical Technology Holdings raised approximately $4.5 million by inducing immediate exercise of existing warran | Jun 30, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K on June 30, 2026, submitting an intimation (Exhibit 99.1) with no material new informati | Jun 30, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K on June 30, 2026, furnishing a press release (Exhibit 99.1). The actual docume | Jun 30, 2026 |
| EVO | 6-K | bullish | 5/10 | Goldman Sachs Group increased its total position in Evotec SE from 12.42% to 14.62% as of June 23, 2026, primarily throu | Jun 30, 2026 |
| BDRX | 6-K | bearish | 4/10 | Biodexa Pharmaceuticals entered into a securities purchase agreement on June 29, 2026, to raise approximately $806,413 t | Jun 30, 2026 |
| RADX | 6-K | neutral | 2/10 | Radiopharm Theranostics filed a 6-K reporting routine ASX notifications: the lapse of 37.2 million unquoted options (RAD | Jun 30, 2026 |
| CELU | 8-K | bearish | 6/10 | Celularity entered into a $1M secured loan agreement with a 5%+ shareholder (Philip Barach Family Trust) bearing 4% inte | Jun 30, 2026 |
| TRIB | 6-K | neutral | 4/10 | Trinity Biotech's subsidiary Trinovium has been granted Silver Membership in the Open Compute Project (OCP), a milestone | Jun 30, 2026 |
| ASND | PRESS-RELEASE | bullish | 5/10 | Ascendis Pharma reported Week 104 data from the pivotal ApproaCH Trial showing continued improvement in lower extremity | Jun 30, 2026 |